MCRB - Seres Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

MCRB is currently covered by 8 analysts with an average price target of $8.48. This is a potential upside of $7.71 (1001.3%) from yesterday's end of day stock price of $0.77.

Seres Therapeutics's activity chart (see below) currently has 49 price targets and 51 ratings on display. The stock rating distribution of MCRB is 94.12% BUY and 5.88% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 37.77% with an average time for these price targets to be met of 78.11 days.

Highest price target for MCRB is $10, Lowest price target is $1.25, average price target is $8.48.

Most recent stock forecast was given by JOHN NEWMAN from CANACCORD on 13-Sep-2024. First documented stock forecast 22-Oct-2015.

Currently out of the existing stock ratings of MCRB, 16 are a BUY (94.12%), 1 are a SELL (5.88%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$10

$8.87 (784.96%)

$10

2 months 10 days ago
(13-Sep-2024)

0/8 (0%)

$9 (900.00%)

Buy

$1.25

$0.12 (10.62%)

$6

3 months 9 days ago
(14-Aug-2024)

0/6 (0%)

$0.35 (38.89%)

Sell

$1.25

$0.12 (10.62%)

$7

1 years 20 days ago
(03-Nov-2023)

4/4 (100%)

$-0.05 (-3.85%)

99

Buy

$12

$10.87 (961.95%)

$13

1 years 4 months 28 days ago
(26-Jun-2023)

4/11 (36.36%)

$6.6 (122.22%)

281

Buy

$12

$10.87 (961.95%)

$29

1 years 6 months 27 days ago
(27-Apr-2023)

3/4 (75%)

$6.68 (125.56%)

38

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is MCRB (Seres Therapeutics) average time for price targets to be met?

On average it took 78.11 days on average for the stock forecasts to be realized with a an average price target met ratio 37.77

Which analyst has the current highest performing score on MCRB (Seres Therapeutics) with a proven track record?

MARK BREIDENBACH

Which analyst has the current lower performing score on MCRB (Seres Therapeutics) with a proven track record?

TAZEEN AHMAD

Which analyst has the most public recommendations on MCRB (Seres Therapeutics)?

Mark Breidenbach has 4 price targets and 2 ratings on MCRB

Which analyst is the currently most bullish on MCRB (Seres Therapeutics)?

Gbola Amusa with highest potential upside - $28.66

Which analyst is the currently most reserved on MCRB (Seres Therapeutics)?

Chris Shibutani with lowest potential downside - $0.12

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?